HDR Focal: Feasibility Study
Condition: Prostate Cancer Interventions: Radiation: targeted focal HDR brachytherapy; Radiation: Whole-gland HDR Brachytherapy Sponsor: University Health Network, Toronto Not yet recruiting - verified September 2016
Radio-recurrent prostate cancer is typically detected by a rising PSA and may reflect local or distant disease. PET radiotracers targeting PSMA such as 18F-DCFPyL have shown promise in restaging men with recurrent disease post-prostatectomy but are less well characterized in the setting of radio-recurrent disease.
Conclusion: LDR-EBRT may provide more effective PSA control at 5 years compared with HDR-EBRT. Direct comparison of these treatments through randomised trials are recommended to investigate this hypothesis further. PMID: 31701035 [PubMed]
AbstractProstate cancer is the most common cancer among men in the USA. Interestingly, recent studies suggest that patients with inflammatory bowel disease (IBD) are at increased risk of developing prostate cancer. Importantly, patients with IBD who develop prostate cancer require thoughtful care when using immunosuppressants to treat the IBD in the setting of malignancy. Further, consideration must be given to the proximity of the prostate to the gastrointestinal tract when treating with radiation where there is concern for the effects of inadvertent exposure of radiation to the diseased bowel. In general, management of i...
Publication date: Available online 9 November 2019Source: Radiation Physics and ChemistryAuthor(s): Farahani Somayeh, Nader Riyahi Alam, Haghgoo Soheila, Shirazi Alireza, Geraily Ghazale, Gorji Ensiye, Kavousi NasibehAbstractOvercoming the tumor radioresistance along with protecting the adjacent normal tissues is considered as the ultimate goal of the radiation therapy. To achieve this goal, extensive studies have demonstrated the radiosensitization potential of the gold nanoparticles (AuNPs) during treatment with low-energy ionizing radiation due to their high-photoelectric absorption coefficient. Compared to the AuNPs, t...
ConclusionCombined HDR-B/EBRT for the treatment of clinically localized prostate cancer provides superb clinical outcomes with excellent 5-year bRFS, dMFS, OS, and late GI/GU toxicity rates.
Spontaneous healing of rectal penetration by SpaceOAR® hydrogel insertion during permanent iodine-125 implant brachytherapy: A case report. Mol Clin Oncol. 2019 Dec;11(6):580-582 Authors: Iinuma K, Mizutani K, Kato T, Nakane K, Tanaka H, Nakano M, Matsuo M, Koie T Abstract Radiation therapy with permanent iodine-125 implant brachytherapy is well established for curable prostate cancer. To maximize the therapeutic potential of brachytherapy, delivered radiation doses have been increased accompanied by refined intraoperative procedures of radioactive seeds placement. However, dose escalation is a do...
Lower sales of its robotic intraoperative radiation therapy system adversely...Read more on AuntMinnie.comRelated Reading: Sensus scores Premier contract for brachytherapy Sensus inks R&D pact with UPenn Sensus touts research for nonmelanoma skin cancer FDA clears Sensus Healthcare's IORT system Sensus names new VP of clinical development
To evaluate focal high dose rate (HDR) brachytherapy in locally recurrent prostate cancer.
ConclusionEBRT + BT was associated with a significantly better prostate CSS compared with surgery or EBRT. EBRT alone was inferior to surgery by OS.
To compare 10-year oncologic treatment outcomes of radical prostatectomy (RP) vs external beam radiation therapy (EBRT) vs brachytherapy (BT) for patients with intermediate risk prostate cancer (IRPC).